Can trial designs be signed electronically?

Yes. Electronic signatures are legally equivalent under the Federal ESIGN Act (15 U.S.C. §7001) and UETA in most states; however certain exceptions apply (e.g., wills, court orders). Confirm whether your specific consent or government filing falls within an ESIGN/UETA exception.

What authentication level is recommended?

For low-risk documents, email or SMS link is often sufficient to demonstrate intent and attribution. For clinical records or regulated submissions consider stronger authentication (multi-factor, KBA) and ensure the platform supports 21 CFR Part 11 controls where required.

Do I need a BAA for PHI?

Yes. When the trial design or workflow handles protected health information, HIPAA requires a Business Associate Agreement between covered entities and vendors who create, receive, maintain, or transmit PHI (see 45 CFR §164.502(e)). Verify vendor BAA terms before sharing PHI.

How long must trial documents be retained?

Retention depends on document type: HIPAA-regulated records six years (45 CFR §164.530(j)); financial records follow IRS minimums (IRC §6501(a)); sponsors commonly retain study records seven years post-closure or longer for product submissions or litigation. Check agency-specific guidance for exceptions.

Are notarization or witnesses required?

Notarization is not routinely required for protocol documents or consent forms, but some jurisdictions or institutional policies may require notarized consents or witness attestations. Remote Online Notarization laws vary by state; verify requirements with the state notary commission before requesting notarization.

What are common submission errors?

Common errors include inconsistent protocol versions, missing or mismatched signatures or dates, incomplete sample size justification, and unclear endpoint definitions. These issues can cause IRB queries, regulatory delays, increased monitoring, and potential rejection of data for primary analyses.

Electronic Signature
Templates
Healthcare
Healthcare Clinical Trial Design

Healthcare Clinical Trial Design

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

What Healthcare Clinical Trial Design Covers

Healthcare Clinical Trial Design is the structured document and protocol set that defines a clinical study's objectives, methodology, endpoints, sample size, inclusion and exclusion criteria, randomization scheme, data collection procedures, monitoring plans, statistical analysis, and safety reporting. It standardizes how investigators and sponsors conduct interventional or observational research, ensures regulatory and ethical compliance with institutional review boards (IRBs) and FDA expectations, and provides the basis for informed consent documents, case report forms, and trial registration. A clear design reduces ambiguity, supports reproducibility, and frames operational timelines and resource needs across study sites.

Why a Clear Trial Design Matters

Well-crafted Healthcare Clinical Trial Design clarifies scientific questions, minimizes protocol deviations, and helps secure IRB approvals and regulatory submissions. It enhances patient safety, streamlines data collection, and reduces the time and cost of study execution while supporting defensible statistical analysis and audit readiness.

Who Typically Prepares and Uses This Design

Research sponsors, principal investigators, clinical operations teams, biostatisticians, and institutional review boards commonly use this design document.

Biopharma sponsors coordinating multi-site randomized controlled trials and adaptive designs.
Academic investigators preparing investigational new drug study protocols for IRB review.
Clinical research organizations (CROs) operationalizing enrollment, monitoring, and data management workflows.

The document also guides contract research, budget planning, vendor selection, and compliance monitoring across study sites.

Step-by-Step: Finalize a Trial Design for Submission

Follow these core steps to create, review, and finalize a Healthcare Clinical Trial Design ready for IRB and regulatory submission.

01

Draft Protocol: Draft objectives, endpoints, and study procedures with clear operational detail.
02

Define Eligibility: List inclusion and exclusion criteria and screening procedures.
03

Plan Analysis: Specify statistical methods, endpoints, and sample size justification.
04

Prepare Submissions: Assemble protocol, informed consent, CRFs, and regulatory attachments.

Configure an Electronic Review and Signature Workflow

Configure an electronic workflow to route the protocol, obtain e-signatures, and capture audit trails for each signer and site.

Field	Configuration
Document Upload Rules	Require PDF/A format, enforce version control and file naming conventions.
Signer Order	Define sequential or parallel routing and fallback options.
Authentication	Select email, SMS code, or KBA for signer verification.
Audit Trail Settings	Capture timestamps, IP addresses, and document event history.

Typical eSubmission Flow for Trial Design Documents

Typical routing for e-submission of a clinical trial design includes upload, field placement, signer authentication, review, and archival.

Upload: Sender uploads protocol and supporting documents to the platform.
Place Fields: Add signature, date, and checkbox fields for each party and site.
Authenticate: Choose authentication level, e.g., email link, SMS code, or KBA.
Complete: Signers execute signatures; system records audit trail and timestamps.

Technical Requirements for eSigning and Records

Electronic workflows require PDF-compatible files, basic signer authentication, and a method to preserve an audit trail for compliance.

Formats: PDF, DOCX, and Excel supported
Integrations: Salesforce, Microsoft 365, NetSuite integrations available
Authentication: Email, SMS, or SSO options

Security and Compliance Essentials

Encryption: TLS 1.2/1.3, AES-256 at rest

Certifications: SOC 2 Type II, ISO 27001, PCI DSS

HIPAA (BAA): BAA required for PHI handling

Audit Trail: Timestamps, IPs, user actions captured

Access Controls: Role-based access and SSO support

Data Retention: Retention controls and exportable logs

Key Risks When a Design Is Incorrect

Protocol Deviations: Compromise validity

IRB Rejection: Study delays

Regulatory Fines: FDA enforcement risk

Data Integrity: Unusable datasets

Patient Harm: Safety incidents

Financial Loss: Increased costs

Common Preparation Pitfalls to Avoid

Vague or poorly specified primary endpoints lead to ambiguous statistical plans and can render study results uninterpretable by regulators or journals.
Failure to document amendment history and protocol versions creates audit issues and complicates reconciliations across sites and data sets.
Inadequate description of safety monitoring, stopping rules, or adverse event reporting increases regulatory risk and delays IRB approvals.
Using inconsistent naming conventions for sites, investigators, or CRFs causes data linkage errors and slows statistical analysis and reporting.

Core Components Every Professional Trial Design Should Include

A complete Healthcare Clinical Trial Design includes scientific rationale, operational procedures, statistical planning, safety oversight, and data management details to satisfy regulatory and ethical review.

Objectives

State primary and secondary objectives with measurable endpoints, timepoints, and hypotheses. Clear objectives align protocol activities, sample size, and statistical methods with regulatory expectations and oversight.

Population

Define inclusion and exclusion criteria, recruitment strategies, and enrollment caps by site. Describe screening, consent procedures, and protections for vulnerable populations documented.

Interventions

Specify investigational product, dosing schedules, administration procedures, blinding methods, and comparator arms. Include accountability and storage requirements for investigational products and handling SOPs across sites.

Assessments

Detail scheduled visits, assessments, data sources, case report forms, and electronic data capture fields. Include timing windows and procedures for missing data and source data verification.

Statistics

Provide statistical analysis plan, handling of multiplicity, interim analyses, sample size calculation, alpha spending, and sensitivity analyses to support claims and data imputation methods and reporting conventions.

Safety

Describe safety monitoring committee, expedited reporting, adverse event grading, stopping rules, and post-study follow-up for participant safety and regulatory compliance including timelines and responsible parties.

Two Practical Examples of Design Impact

Real-world examples show how design clarity reduces review cycles and improves data quality across sponsors and sites.

Multi-center RCT

A multi-center randomized controlled trial standardized protocol templates across 12 sites, reducing onboarding variation and ensuring consistent data collection instruments.

Harmonized CRFs and training reduced query rates.
Standardized design language and centralized version control enabled the sponsor to merge datasets without manual reconciliation, shortened the data cleaning window, and improved the integrity of pooled analyses submitted to the FDA.

Adaptive Oncology Trial

An adaptive oncology trial incorporated prespecified interim analyses, allowing dose adjustments and cohort expansion based on predefined efficacy thresholds.

Interim stopping rules emphasized safety and efficiency.
Clear statistical plans and stopping criteria reduced regulator questions, compressed the review timeline, and provided transparent decision-making that facilitated rapid amendments and continuation of promising cohorts under IRB oversight.

Time-Sensitive Deadlines and Expectations

Key deadlines include IRB submission, site activation, enrollment windows, interim analyses, and regulatory safety reporting timelines required by agencies and sponsors.

IRB Submission:

Allow four to eight weeks for full-board review depending on site schedules.

Site Activation:

Budget for two to six weeks after IRB approval for contracts and training.

Enrollment Window:

Specify planned recruitment period and contingency for slower-than-expected accrual.

Interim Analyses:

Prespecified timing and stopping rules must be in SAP and protocol.

Safety Reporting:

Report SUSARs and SAEs per FDA timelines and IRB requirements.

Key Milestones from Protocol to Closeout

Sequential milestones from protocol finalization through closeout clarify responsibilities and schedule key regulatory and operational events.

01

Protocol Finalization

Complete protocol, SAP, and essential documents ready for submission.

02

IRB Approval

Obtain approvals or exemptions for each participating site.

03

First Subject In

Begin enrollment after site activation and consent processes are complete.

04

Database Lock

Complete data cleaning and lock database before final analysis.

eSignature Vendor Comparison for Clinical Trial Workflows

Side-by-side vendor pricing and feature summary to inform eSignature selection for Healthcare Clinical Trial Design processes; signNow appears first per table convention.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial, no credit card required	Varies by vendor and plan; contact sales	Varies by vendor and plan; contact sales	Varies by vendor and plan; contact sales	Varies by vendor and plan; contact sales
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Frequently Asked Questions About Trial Design Documents

Answers to common questions about preparing, signing, and maintaining Healthcare Clinical Trial Design documents in U.S. regulatory contexts.

Need help? Contact support

Can trial designs be signed electronically?
Yes. Electronic signatures are legally equivalent under the Federal ESIGN Act (15 U.S.C. §7001) and UETA in most states; however certain exceptions apply (e.g., wills, court orders). Confirm whether your specific consent or government filing falls within an ESIGN/UETA exception.
What authentication level is recommended?
For low-risk documents, email or SMS link is often sufficient to demonstrate intent and attribution. For clinical records or regulated submissions consider stronger authentication (multi-factor, KBA) and ensure the platform supports 21 CFR Part 11 controls where required.
Do I need a BAA for PHI?
Yes. When the trial design or workflow handles protected health information, HIPAA requires a Business Associate Agreement between covered entities and vendors who create, receive, maintain, or transmit PHI (see 45 CFR §164.502(e)). Verify vendor BAA terms before sharing PHI.
How long must trial documents be retained?
Retention depends on document type: HIPAA-regulated records six years (45 CFR §164.530(j)); financial records follow IRS minimums (IRC §6501(a)); sponsors commonly retain study records seven years post-closure or longer for product submissions or litigation. Check agency-specific guidance for exceptions.
Are notarization or witnesses required?
Notarization is not routinely required for protocol documents or consent forms, but some jurisdictions or institutional policies may require notarized consents or witness attestations. Remote Online Notarization laws vary by state; verify requirements with the state notary commission before requesting notarization.
What are common submission errors?
Common errors include inconsistent protocol versions, missing or mismatched signatures or dates, incomplete sample size justification, and unclear endpoint definitions. These issues can cause IRB queries, regulatory delays, increased monitoring, and potential rejection of data for primary analyses.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now

Healthcare Clinical Trial Design